Role of proteolytic enzymes and their inhibitors in tumor progression and in pregnancy

Experimental Oncology

Volumn 19, Issue 1, 1997, Pages 7-19

  Surgova, T M ^a   Sidorenko, M V ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Glycosylation; Pregnancy proteins; Proteinase; Proteinase inhibitor; Tumor

Indexed keywords

EID: 3343008005     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Bignami A, LeBlanc A, Perides G. A role of extracellular matrix degradation and matrix metalloproteinases in senile dementia. Acta Neuropathol (Berl) 1994; 87: 308-12.
2. Mignatti P, Psuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1988; 108: 671-82.
3. Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Sem Cancer Biol 1990; 1: 137-52.
4. Seambia G, Panici PB, Ferrandia G et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 1994; 30A: 935-9.
5. Johnson MD, Torri JA, Lippman ME, Dickinson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993; 53: 873-7.
6. Tetu B, Brisson J, Cote Ch et al. Prognostic significance of cathepsin D expression in node positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993; 55: 429-35.
7. Murphy GJ, Murphy G, Reynolds JJ. The origin of metalloproteinases and their familial relationships. FEBS Lett 1991; 289: 4-7.
8. Emonard HP, Remacle AG, Noeel AC et al. Tumor cell surface associated binding site for (the M9r) 72,000 type IV collagenase. Cancer Res 1992; 52: 5845-48.
9. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
10. De Clerck YA, Imren YA. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994; 38A: 2170-80.
11. Rivett AJ. The multicatalytic proteinase of mammalian cells. Arch Biochem Biophys 1988; 268: 1-8.
12. Tanaka K, Li K, Ichihara A et al. A high molecular weight protease in the cytosol of rat liver. J Biol Chem 1986; 261: 15197-203.
13. Tanaka K, Ichichara A. Proteasomes (multicatalytic proteinase complexes) in eukaryotic cells. Cell Struct Funct 1990; 15: 127-32.
14. King LE, Gates RE. Calcium-activated neutral protease purified from beef lung: properties and use in defining structure of epidermal growth factor receptors. Arch Biochem Biophys 1985; 242: 146-56.
15. Kishimoto A, Kajikawa N, Shiota M, Nishizuka Y. Proteolytic activation of calcium-activated phospholipid-dependent protein kinase by calcium-dependent neutral protease. J Biol Chem 1983; 258: 1156-64.
16. Sakai K, Akanuma H, Imahori K, Kawashima S. A unique specificity of a calcium activated neutral protease indicated in histone hydrolysis. J Biochem 1987; 101: 911-8.
17. Imajoh S, Kawasaki H, Emori Y, Suzuki L. Calcium-activated neutral protease inhibitor from rabbit erythrocytes lacks the N-terminal region of the liver inhibitor but retains three inhibitory units. Biochem Biophys Res Commun 1987; 146: 630-7.
18. Murachi T. Intracellular regulatory system involving calpain and calpastatin. Biochem Int 1989; 18: 263-94.
19. Melloni E, Salamino F, Sparatore B. The calpain-calpastatin system in mammalian cells: properties and possible functions. Biochimie 1992; 74: 217-23.
20. Gregoriou M, Willis AC, Pearson MA, Crawford C. The calpain cleavage sites in the epidermal growth factor receptor kinase domain. Eur J Biochem 1994; 223: 455-64.
21. Chen WS, Lazar CS, Lund KA et al. Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced and calcium regulation. Cell 1989; 59: 33-43.
22. Countaway YL, Nairn AC, Davis RY. Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase. J Biol Chem 1992; 267: 1129-40.
23. Fry M, Panayotou G, Booker G, Waterfield M. New insights into protein-tyrosine kinase receptor signalling complexes. Prot Sci 1993; 2: 1785-97.
24. Felder S, LaVin J, Ullrich A, Schlessinger J. Kinetics of binding, endocytosis and recycling of EGF receptor mutants. J Cell Biol 1992; 117: 203-12.
25. Futter CE, Felder S, Schlessinger J et al. Annexin I phosphorylated in the multivesicular body during the processing of the epidermal growth factor receptor. J Cell Biol 1993; 120: 77-83.
26. Sunada H, Peacock JS, Mendelsohn J. Modulation of tyrosine, serine and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol 1990; 142: 284-92.
27. Kay DJ, Lai WH, Uchihashi M et al. Epidermal growth factor receptor kinase translocation and activation in vivo. J Biol Chem 1986; 261: 8473-80.
28. Wells A, Welsh JB, Lazar CS et al. Ligand-induced transformation by a non-internalizing epidermal growth factor receptor. Science 1990; 247: 962-4.
29. Seger R, Yarden Y, Kashles O et al. The epidermal growth factor receptor as a substrate for a kinase-splitting membrane proteinase. J Biol Chem 1988; 263: 3496-500.
30. DeWolf F, DeWolf-Peeters C, Brosens I, Robertson WB. The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. Am J Obstet Gynecol 1980; 137: 58-65.
31. Brosens JA. The utero-placental vessels at term. The distribution and extent of physiologic changes. In: Kaufmann P, Miller RH, eds. Trophoblast Research. New York: Plenum, 1988; 3: 61-84.
32. Queenan JT, Kao LC, Arboleda CE et al. Regulation of urokinase-type plasminogen activator production by cultured human cytotrophoblasts. J Biol Chem 1987; 262: 10903-6.
33. Strickland S, Reich E, Sherman MJ. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell 1976; 9: 231-7.
34. Saksela O. Plasminogen activator and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-42.
35. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997-6007.
36. Liotta LA, Goldfarb RH, Brundage R et al. Effect of plasminogen activators (urokinase), plasmin and thrombin on glycoprotein and collagenous components of the basement membrane. Cancer Res 1991; 41: 4629-39.
37. Zini JM, Murray SC, Graham CH et al. Characterization of urokinase receptor expression by human placental trophoblasts. Blood 1992; 79: 2917-29.
38. Estreicher A, Wohlwend A, Belin D et al. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1988; 263: 1180-4.
39. Ellis V, Scully MF, Kakkar VV. Plasminogen activation, induced by single chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-7.
40. Chapman HA, Jr, Bertozzi P, Sailor LZ, Nusrat AR. Alveolar macrophage urokinase receptors localize enzymatic activity to the cell surface. Am J Physiol 1990; 259: 432-3.
41. Ploug M, Ronne E, Behrendt N et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 1926-8.
42. Stoppelli MP, Tacchetti C, Cubelius MV et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45: 675-85.
43. Gettins P, Patston PA, Schapira M. Structure and mechanism of action of serpins. Hematol Oncol Clin North Am 1992; 6: 1393-408.
44. Barker AF. Alpha-1-antitrypsin-deficiency-related emphysema. J Am Board Fam Pract 1992; 5: 489-93.
45. Wulfsberg EA, Hoofmann DE, Cohen MM. Alpha-1-antitrypsin deficiency. Impact of genetic discovery on medicine and society. JAMA 1994; 271: 217-22.
46. Bode W, Huber R. Natural protein-proteinase inhibitors and their interaction with proteinases. Eur J Biochem 1992; 204: 433-51.
47. Barrett AJ. The cystatins: a new class of peptidase inhibitors. Trends Biochem Sci 1987; 12: 193-6.
48. Keil-Dlouha V, Planchenault T. Potential proteolytic activity of human plasma fibronectin. Proc Nat Acad Sci USA 1986; 83: 5377-81.
49. Murphy G, Reynolds JJ. Current views of collagen degradation. Bioassays 1985; 2: 55-60.
50. Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invas Metastas 1989; 9: 391-405.
51. Denhardt DT, Edwards DR, Parfett CLJ. Gene expression during the mammalian cell cycle. Biochim Biophys Acta 1986; 865: 83-125.
52. Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72-kDa progelatinase and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem 1989; 264: 1860-9.
53. Hicks NJ, Ward RV, Reynolds JJ. A fibrosarcoma model derived from embryo cells: growth properties and secretion of collagenase and metalloproteinase inhibitor (TIMP) by tumor cell lines. Int J Cancer 1984; 33: 835-44.
54. Thorgeirsson UP, Liotta LA, Kalebic T et al. Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro. J Nat Cancer Inst 1982; 69: 1049-54.
55. Jensen PEH, Stigbrand T. Differences in the proteinase inhibition mechanism of human alpha2-macroglobulin and pregnancy zone protein. Eur J Biochem 1992; 210: 1071-7.
56. Sand O, Folkersen J, Westergaard JG, Sottrup-Jensen L. Characterization of human pregnancy zone protein. J Biol Chem 1985; 260: 15723-35.
57. Salvesen GS, Barrett AJ. Covalent binding of proteinases in their reaction with alpha2-macroglobulin. Biochem J 1980; 187: 695-701.
58. Gettins P, Sottrup-Jensen L. NMR and ESR studies on human pregnancy zone protein. J Biol Chem 1990; 265: 7268-72.
59. VanLeuven F, Cassiman JJ, Van den Berghe H. Human pregnancy zone protein and alpha2-macroglobulin. J Biol Chem 1986; 261: 16622-5.
60. Borth W. Alpha2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 1992; 6: 3345-53.
61. Chu CT, Pizzo SV. Receptor-mediated antigen delivery into macrophages. J Immunol 1993; 150: 48-58.
62. Feldman SR, Rosenberg MR, Ney KA et al. Binding of alpha2-macroglobulin to hepatocytes mechanism of in vivo clearance. Biochem Biophys Res Commun 1985; 128: 795-802.
63. Moestrup SK, Gliemann J. Purification of the rat hepatic alpha2-macroglobulin receptor as an approximately 440 kDa single chain protein. J Biol Chem 1989; 264: 15574-7.
64. Ashcom JD, Tiller SE, Dickerson K et al. The human alpha2-macroglobulin receptor identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha2-macroglobulin. J Cell Biol 1990; 110: 1041-8.
65. Herz J, Hamann U, Rogne S et al. Surface location and high affinity for calcium of a 500-kD liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988; 7: 4119-27.
66. Moestrup SK, Nielsen S, Andreasen PA et al. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes J Biol Chem 1993; 268: 16564-70.
67. Willnow TE, Goldstein JL, Orth K et al. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylimicron remnant clearance. J Biol Chem 1992; 267: 26172-80.
68. Kounnas MZ, Argraves WS, Strickland DK. The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha2-macroglobulin receptor and glycoprotein 330. J Biol Chem 1992; 267: 21162-6.
69. Chatelet F, Brianti E, Ronco P et al. Ultrastructural localization by monoclonal antibodies of brush border antigens expressed by glomeruli. I. Renal distribution. Am J Pathol 1986; 122: 500-11.
70. Gliemann J, Davidsen O. Characterization of receptors for alpha2-macroglobulin-trypsin complex in rat hepatocytes. Biochem Biophys Acta 1986; 885: 49-7.
71. Moestrup SK, Christensen El, Sottrup-Jensen L, Gliemann J. Binding and receptor-mediated endocytosis of pregnancy zone protein-proteinase complex in rat macrophages. Biochim Biophys Acta 1987; 930: 297-303.
72. Mizra UK, Chu CT, Rubenstein DS et al. Receptor-recognized alpha2-macroglobulin-methylamine elevates intracellular calcium, inositol phosphates and cyclic AMP in murine peritoneal macrophages. Biochem J 1993; 290: 885-91.
73. Hussaini IM, Srikumar K, Quesenberry PJ. Colony-stimulating factor-1 modulates alpha2-macroglobulin receptor expression in murine bone-marrow macrophages. J Biol Chem 1990; 265: 1441-6.
74. Moestrup SK. The alpha2-macroglobulin receptor and endothelial glycoprotein-330: two giant receptors mediating endocytosis of multiple ligands. Biochim Biophys Acta 1994; 1197: 197-213.
75. Moestrup SK, Kaltoft K, Petersen CM et al. Immunochemical identification of the human alpha2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen. Exp Cell Res 1990; 190: 195-203.
76. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 1992; 71: 411-21.
77. Roldan AL, Cubellis MV, Masucci MT et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
78. Nykjaer A, Petersen CM, Moller B et al. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells. FEBS Lett 1993; 300: 13-7.
79. Joslin G, Wittwer A, Adams S et al. Cross-competition for binding of alpha1-antitripsin-elastase complexes to the serpin-enzyme complexes receptor by other serpin-enzyme complexes and by proteolytically modified alpha1-AT. J Biol Chem 1993; 68: 1886-93.
80. Davidsen O, Gliemann J. The plasma clearance of human alpha2-macroglobulin-trypsin complexes in the rat is mainly accounted for by uptake into hepatocytes. Biochim Biophys Acta 1985; 846: 85-92.
81. Moestrup SK, Hokland P. Surface expression of the alpha2-macroglobulin receptor on human malignant blood cells. Leukemia Res 1992; 16: 227-34.
82. Poulson R, Pignatelli M, Stetler Stevenson WG et al. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-96.
83. Nabeshima K, Lane WS, Biswas C. Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor. Arch Biochem Biophys 1994; 285: 90-6.
84. Vassali JD, Pepper MS. Tumour biology. Membrane proteases in focus. Nature 1994; 379: 14-5.
85. Hakomori S. Aberrant Glycosylation in Tumors: Altered Glycosylation in Tumor Cells. Cold Spring Harbor: Alan R. Liss, Inc. 1988: 207-12.
86. Montgomery AM, De Clerck YA, Langley KE et al. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 1993; 53: 693-700.